Experienced in Insulinoma

Dr. Raul R. Mena

Hematology Oncology
181 S Buena Vista St, 4rth Floor, 
Burbank, CA 
Experienced in Insulinoma
181 S Buena Vista St, 4rth Floor, 
Burbank, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raul Mena is a Hematologist Oncology provider in Burbank, California. Dr. Mena is rated as an Experienced provider by MediFind in the treatment of Insulinoma. His top areas of expertise are Lung Cancer, Adult Soft Tissue Sarcoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Endoscopy.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

181 S Buena Vista St, 4rth Floor, Burbank, CA 91505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Journal: British journal of haematology
Published: September 13, 2019
Similar Doctors
Experienced in Insulinoma
Dr. Saro S. Kasparian
Hematology Oncology | Hematology | Oncology
Experienced in Insulinoma
Dr. Saro S. Kasparian
Hematology Oncology | Hematology | Oncology

Los Angeles Hematology-Oncology Medical Group

1505 Wilson Ter, Suite 200, 
Glendale, CA 
 (5.7 miles away)
818-409-0105
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Saro Kasparian is a Hematologist Oncology specialist and a Hematologist in Glendale, California. Dr. Kasparian is rated as an Advanced provider by MediFind in the treatment of Insulinoma. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Chronic Familial Neutropenia, and Thrombocytopenia.

Tara E. Seery
Experienced in Insulinoma
Dr. Tara E. Seery
Hematology Oncology
Experienced in Insulinoma
Dr. Tara E. Seery
Hematology Oncology

Hoag Clinic

1 Hoag Dr, 
Newport Beach, CA 
 (43.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tara Seery is a Hematologist Oncology provider in Newport Beach, California. Dr. Seery is rated as a Distinguished provider by MediFind in the treatment of Insulinoma. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, Ampullary Cancer, Pancreatoblastoma, and Cholangiocarcinoma (Bile Duct Cancer).

Experienced in Insulinoma
Dr. Daniel J. Kim
Hematology Oncology | Oncology | Hematology
Experienced in Insulinoma
Dr. Daniel J. Kim
Hematology Oncology | Oncology | Hematology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (10.5 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Kim is a Hematologist Oncology specialist and an Oncologist in South Pasadena, California. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Insulinoma. His top areas of expertise are Stomach Cancer, Chronic Familial Neutropenia, Agranulocytosis, and Blood Clots.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mena's expertise for a condition
ConditionClose
    View All 30 Advanced Conditions
    View All 132 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile